Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to cool inflammation in heart arteries after attack

NCT ID NCT06927739

Recruiting now Disease control Sponsor: Abcentra Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a drug called orticumab in 240 people who had a heart attack and still have high inflammation in their heart arteries. Participants receive either orticumab or a placebo for 24 weeks. The main goal is to see if orticumab lowers inflammation measured by a special CT scan. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
orticumab
What this could lead to
If it works, this could lead to a new treatment that reduces dangerous inflammation in heart arteries after a heart attack, potentially lowering the risk of future heart problems.
What could go wrong
This is an early phase 2 trial with only 240 participants, so results may not apply to everyone. The drug may not reduce inflammation better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder coronary atherosclerosis heart disorder Inflammation inflammatory disease myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROMES ATHEROSCLEROTIC CORONARY VASCULAR DISEASE CORONARY ARTERIAL DISEASE (CAD) HEART DISEASE INFLAMMATION MYOCARDIAL INFARCT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Abcentra Investigational Site

    NOT_YET_RECRUITING

    Los Angeles, California, 90048, United States

  • Abcentra Investigational Site

    RECRUITING

    Torrance, California, 90502, United States

  • Abcentra Investigational Site

    RECRUITING

    Boca Raton, Florida, 33434, United States

  • Abcentra Investigational Site

    RECRUITING

    Richmond, Indiana, 47374, United States

  • Abcentra Investigational Site

    NOT_YET_RECRUITING

    Louisville, Kentucky, 40202, United States

  • Abcentra Investigational Site

    RECRUITING

    Baltimore, Maryland, 21215, United States

  • Abcentra Investigational Site

    RECRUITING

    Midland, Michigan, 48670, United States

  • Abcentra Investigational Site

    RECRUITING

    Ostrava, Moravian-Silesian Region, 728 80, Czechia

  • Abcentra Investigational Site

    RECRUITING

    Pilsen, Plzeň Region, 323 00, Czechia

  • Abcentra Investigational Site

    RECRUITING

    Prague, Praha 2, 128 08, Czechia

  • Abcentra Investigational Site

    RECRUITING

    Prague, Praha 4, 140 21, Czechia

  • Abcentra Investigational Site

    RECRUITING

    Brno, South Moravian, 602 00, Czechia

  • Abcentra Investigational Site

    RECRUITING

    Pécs, Baranya, 7635, Hungary

  • Abcentra Investigational Site

    RECRUITING

    Budapest, Central Hungary, 1036, Hungary

  • Abcentra Investigational Site

    RECRUITING

    Budapest, Central Hungary, 1094, Hungary

  • Abcentra Investigational Site

    RECRUITING

    Budapest, Central Hungary, 1132, Hungary

  • Abcentra Investigational Site

    RECRUITING

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary

  • Abcentra Investigational Site

    RECRUITING

    Caserta, Campania, 81100, Italy

  • Abcentra Investigational Site

    RECRUITING

    Ferrara, Ferrara, 44124, Italy

  • Abcentra Investigational Site

    RECRUITING

    Brescia, Lombardy, 25123, Italy

  • Abcentra Investigational Site

    RECRUITING

    Milan, Lombardy, 20162, Italy

  • Abcentra Investigational Site

    RECRUITING

    Pavia, Lombardy, 27100, Italy

  • Abcentra Investigational Site

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-082, Poland

  • Abcentra Investigational Site

    RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • Abcentra Investigational Site

    RECRUITING

    Warsaw, Masovian Voivodeship, 03-505, Poland

  • Abcentra Investigational Site

    RECRUITING

    Baia Mare, Maramureş, 430031, Romania

  • Abcentra Investigational Site

    RECRUITING

    Târgu Mureş, Mureș County, 540124, Romania

  • Abcentra Investigational Site

    RECRUITING

    Timișoara, Timiș County, 300060, Romania

  • Abcentra Investigational Site

    RECRUITING

    Córdoba, Andalusia, 14004, Spain

  • Abcentra Investigational Site

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • Abcentra Investigational Site

    RECRUITING

    Madrid, Madrid, 28046, Spain

  • Abcentra Investigational Site

    RECRUITING

    El Palmar, Murcia, 30120, Spain

  • Abcentra Investigational Site

    RECRUITING

    Seville, Sevilla, 41009, Spain

  • Abcentra Investigational Site

    RECRUITING

    Danderyd, Stockholm County, 182 88, Sweden

  • Abcentra Investigational Site

    RECRUITING

    Solna, Stockholm County, 171 76, Sweden

  • Abcentra Investigational Site

    RECRUITING

    Gothenburg, Västra Götaland County, 413 45, Sweden

  • Abcentra Investigational Site

    RECRUITING

    London, Greater London, EC1M 6BQ, United Kingdom

  • Abcentra Investigational Site

    RECRUITING

    Manchester, Greater Manchester, M23 9LT, United Kingdom

  • Abcentra Investigational Site

    RECRUITING

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

  • Abcentra Investigational Site

    RECRUITING

    Bath, Somerset, BA1 3NG, United Kingdom

  • Abcentra Investigational Site

    RECRUITING

    Sheffield, South Yorkshire, S57AU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.